Lixisenatida en pacientes con diabetes tipo 2 y obesidad: más allá del control glucémico

Abstract

AimTo evaluate tolerance to lixisenatide and its effects on weight and metabolic control in type2 diabetes and obese patients. DesignProspective study. SettingEndocrinology clinics in Almeria, Granada and Malaga. ParticipantsPatients with type2 diabetes and obesity. InterventionsResponse and tolerance to lixisenatide treatment. Main measurementsClinical and analytical data of the subjects were evaluated at baseline and after treatment. ResultsThe study included 104 patients (51% women) with type2 diabetes and obesity (Almeria 18.3%; Granada 40.4%; Malaga 41.3%). The mean age was 58.4±10.5years, and the mean duration of diabetes was 11.2±6.7years. The patients were re-evaluated at 3.8±1.6months after treatment with lixisenatide. Significant improvements were found in weight (P<.001), body mass index (P<.001), waist circumference (P=.002), systolic blood pressure (P<.001), diastolic blood pressure (P=.001), fasting glucose (P<.001), HbA1c (P=.022), Total cholesterol (P<.001), LDL-cholesterol (P=.046), triglycerides (P=.020), hypertension drugs (P<.001), and lipids drugs (P<.001). No changes were observed in levels of amylase related to lixisenatide treatment, and 7.9% of patients did not tolerate it. ConclusionsLixisenatide achieved significant improvements in anthropometric parameters, glycaemic control (fasting glucose and HbA1c), blood pressure and lipids. It was safe and well tolerated in most patients. In addition, there was a significant increase in the use of antihypertensive and lipid-lowering therapy.